Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy
NCT06427798
Recruiting
Background: Gastrointestinal neuroendocrine tumors (GI NET) are a type of cancer that affects the stomach and intestines; pheochromocytoma/paragangliomas (PPGL) are tumors that grow in or near the adrenal glands. Both of these types of tumor have high levels of a protein called somatostatin receptors (SSTR) on their surfaces. Researchers want to test a treatment that targets SSTR. Objective: To test a drug (\[212Pb\]VMT-alpha-NET) in people with GI NET or PPGL. The drug has 2 components: a pr... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
04/04/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma, Paragangliomas
Register for Updates
A Study to Assess the Efficacy and Safety of Induction Therapy With RO7790121 in Participants With Moderately to Severely Active Crohn's Disease
NCT06819891
Recruiting
This Phase III, multicenter, double-blind, placebo-controlled study will evaluate the efficacy and safety of induction therapy with RO7790121 in participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
04/04/2025
Locations: Eminat Research Group, Miramar, Florida
Conditions: Moderately to Severely Active Crohns Disease
Register for Updates
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT04840589
Recruiting
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: National Cancer Institute Developmental Therapeutics Clinic, Bethesda, Maryland +6 locations
Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Register for Updates
Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL
NCT05952024
Recruiting
The study will measure the safety, tolerability, and efficacy with acalabrutinib in combination with rituximab in treatment-naïve elderly and/or frail patients with diffuse large B-cell lymphoma (DLBCL), who are otherwise unsuitable for standard front line chemoimmunotherapy treatments.
Gender:
ALL
Ages:
Between 65 years and 99 years
Trial Updated:
04/04/2025
Locations: Research Site, La Jolla, California +51 locations
Conditions: Diffuse Large B-Cell Lymphoma
Register for Updates
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT06433947
Recruiting
Phase 1b, open-label study evaluating the safety, tolerability, pharmacokinetics, preliminary antitumor activity, and pharmacodynamics of OPN-6602 monotherapy and in combination with dexamethasone in subjects with relapsed and/or refractory MM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Banner MD Anderson, Gilbert, Arizona +7 locations
Conditions: Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Register for Updates
Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use
NCT06829238
Recruiting
This randomized clinical trial (RCT) evaluates whether metformin can reduce systemic inflammation and improve immune function in individuals with a history of injection drug use, with or without HIV. Participants will receive metformin or placebo and undergo immune system assessments, including vaccine response evaluations.
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
04/04/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Systemic Inflammation, Immune Dysregulation, Injection Drug Use, HIV
Register for Updates
PLAN Intervention to Enhance Engagement of Latino Cancer Patients in Advanced Care Planning
NCT04889144
Recruiting
This trial tests whether Planning for Your Advance Care Needs (PLAN) intervention works to enhance Latino patients' understanding of and engagement in advanced care planning. The PLAN intervention may be an effective method to help people with cancer plan for and talk about advance care planning (the care they would want if they were unable to communicate) with their loved ones and doctors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Weill Cornell Medicine, New York, New York +3 locations
Conditions: Locally Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm
Register for Updates
A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer
NCT06007937
Recruiting
This study will test the safety of the combination of ramucirumab and lorlatinib. The researchers will test one or two different doses of lorlatinib in combination with ramucirumab to find the drug combination dose that causes few or mild side effects in participants. Once the researchers find this dose, they can test it in future participants to see if it is effective in treating their metastatic ALK-rearranged NSCLC. The researchers are also looking to see whether there are specific genes or D... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
04/04/2025
Locations: Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey +5 locations
Conditions: Non Small Cell Lung Cancer, Metastatic, Recurrent
Register for Updates
Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease
NCT06456593
Recruiting
This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the sa... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
04/04/2025
Locations: IMC Gulf Coast Gastroenterology, PC, Fairhope, Alabama +140 locations
Conditions: Moderately to Severely Active Crohn Disease
Register for Updates
Patient-reported Outcomes of Donor Site Healing Using Different Palatal Protection Techniques
NCT06892496
Recruiting
This study has been initiated to evaluate the question, "What is the best way to protect the palate after a gum graft is removed?" The overall objective is to determine if there is a difference in PROMs of donor site healing using different palatal post-operative protection techniques.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Mucosal Erosion, Gingival Recession
Register for Updates
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
NCT04929223
Recruiting
This open-label, exploratory study is designed to evaluate the safety and efficacy of targeted therapies or immunotherapy as single agents or combinations, in participants with metastatic colorectal cancer (mCRC) whose tumors are biomarker positive as per treatment arm-specific definition. Eligible participants with mCRC will be enrolled into specific treatment arms based on their biomarker assay results.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: UAB Comprehensive Cancer Center, Birmingham, Alabama +72 locations
Conditions: Metastatic Colorectal Cancer
Register for Updates
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936
Recruiting
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/04/2025
Locations: Alta Bates Summit Medical Center, Berkeley, California +72 locations
Conditions: Lymphoma
Register for Updates